Modified vaccinia ankara
- Generic Name
- Modified vaccinia ankara
- Brand Names
- Jynneos
- Drug Type
- Biotech
- Unique Ingredient Identifier
- TU8J357395
- Background
Modified Vaccinia Ankara (MVA) refers to an attenuated strain of the Vaccinia virus. Vaccines using MVA are live and non-replicating, and are produced using Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN).
- Indication
Modified vaccinia ankara is a vaccine indicated for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox infection. In the EU, it is additionally indicated for the prevention of other diseases caused by the vaccinia virus.
- Associated Conditions
- Ebola Virus Disease, Monkeypox, Variola Major (Smallpox)
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
- Conditions
- Systemic InflammationImmune DysregulationInjection Drug UseHIV
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 100
- Registration Number
- NCT06829238
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Bavarian Nordic
- Target Recruit Count
- 460
- Registration Number
- NCT06549530
- Locations
- 🇨🇩
University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the
🇺🇬Uganda Virus Research Institute, Entebbe, Uganda
🇺🇬Epicentre Mbarara Research Centre, Mbarara, Uganda
A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-05-21
- Target Recruit Count
- 450
- Registration Number
- NCT05740982
- Locations
- 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸Duke Vaccine and Trials Unit, Durham, North Carolina, United States
Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-04-20
- Target Recruit Count
- 229
- Registration Number
- NCT05512949
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸University of California, San Diego (UCSD) - Antiviral Research Center (AVRC), San Diego, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Adults
- Conditions
- Malaria
- Interventions
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 30
- Registration Number
- NCT05441410
Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
- Conditions
- Colorectal CarcinomaLynch Syndrome
- Interventions
- Biological: Adenoviral Tumor-specific Neoantigen Priming Vaccine GAd-209-FSPProcedure: Biospecimen CollectionProcedure: Endoscopic BiopsyOther: Questionnaire Administration
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT05078866
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
- Conditions
- Yellow FeverYellow Fever Immunisation
- Interventions
- Drug: ISA-720Other: PlaceboBiological: MVA-BN Yellow Fever VaccineBiological: YF Vax 17D Strain
- First Posted Date
- 2016-04-19
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 92
- Registration Number
- NCT02743455
- Locations
- 🇺🇸
University of Iowa - Vaccine Research and Education Unit, Iowa City, Iowa, United States
🇺🇸Saint Louis University Center for Vaccine Development, Saint Louis, Missouri, United States
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal CancerEpstein Barr Virus Infections
- First Posted Date
- 2013-02-27
- Last Posted Date
- 2018-07-17
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 22
- Registration Number
- NCT01800071
- Locations
- 🇬🇧
University of Birmingham, Edgbaston, Birmingham, United Kingdom
🇬🇧Royal Marsden Hospital, Fulham Road, London, United Kingdom
🇬🇧Velindre Cancer Centre, Cardiff, United Kingdom
Modified Vaccinia Ankara (MVA) Vaccine Study
- Conditions
- Nasopharyngeal NeoplasmsEpstein-Barr Virus Infections
- Interventions
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2011-12-22
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 18
- Registration Number
- NCT01256853
- Locations
- 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine
- First Posted Date
- 2007-04-27
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 590
- Registration Number
- NCT00466245
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.